Gsk1120212

Manufactured by Chemietek

Sourced in United States

The GSK1120212 is a laboratory instrument designed for performing various analytical and research tasks. It is a versatile piece of equipment that can be used in a wide range of scientific disciplines. The core function of this product is to provide accurate and reliable data processing and analysis capabilities to support scientific research and development.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using gsk1120212

Cell Culture and Compound Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

A375, 293T, SKMEL-19, and WM266.4 cells were grown in DMEM with 10% FBS. A375 and 293T cells were acquired from the ATCC. WM266.4 cells were acquired through the Cancer Cell Line Encyclopedia (20 ). SKMEL-19 cells were a gift from N. Rosen (Memorial Sloan Kettering Cancer Center, New York, NY). GSK1120212, GSK2118436, VX-11e, and AZD6244 were obtained from Chemietek. PLX4720 was obtained from Selleck. SCH772984 was synthesized by J & W PharmLab. Lentiviral production and infection were performed as previously described (19 (link)).

Goetz E.M., Ghandi M., Treacy D.J., Wagle N, & Garraway L.A. (2014). ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors. Cancer research, 74(23), 7079-7089.

+ Open protocol

+ Expand

Evaluating Efficacy of Targeted Therapies

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

NVP-BEZ235 (BEZ235), NVP-BKM120 (Buparlisib, BKM120), GSK1120212 (Trametinib, JTP-74057), PD0325901, and AZD6244 were purchased from Chemie Tek (Indianapolis, IN). Temozolomide, doxorubicin and paclitaxel were purchased from Sigma. For in vivo studies, BEZ235 and BKM120 were resuspended in NMP (N-methyl-2-pyrrolidone):PEG300 1:9 v:v, and GSK1120212 and PD0325901 were resuspended in 0.5% hydroxypropyl-methylcellulose (Sigma):0.2% Tween 80 (Sigma) (Gilmartin et al., 2011 (link); Kinross et al., 2011 (link)). BKM120, GSK1120212 and PD0325901 were given once daily by oral gavage at 10 ml/kg. Mice were treated with BEZ235 on a 5 days on, 2 days off schedule (Liu et al., 2009 (link)). Vehicle- and drug-treated mice were closely monitored on a daily basis for clinical signs as described above.

El Meskini R., Iacovelli A.J., Kulaga A., Gumprecht M., Martin P.L., Baran M., Householder D.B., Van Dyke T, & Weaver Ohler Z. (2014). A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Disease Models & Mechanisms, 8(1), 45-56.

+ Open protocol

+ Expand

Western Blot Analysis of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against AKT, p‐AKT^Ser473, p‐AKT^Thr308, mTOR, p‐mTOR^Ser2448, p‐4E‐BP1^Thr37/46, eIF4E, p‐eIF4E, S6, p‐S6^Ser235/236, ERK1/2, p‐ERK 1/2, p‐Rb, Bcl‐2 family proteins (including p‐Bad^Ser112 (data shown) and Ser136), and cyclin E were obtained from Cell Signaling Technologies (Danvers, MA, USA). Anti‐cyclin D1 was from Abcam (Cambridge, MA, USA). Anti‐β‐actin was obtained from Sigma‐Aldrich (St. Louis, MO, USA). PI3K/mTOR dual inhibitor NVP‐BEZ235 (Dactolisib) was purchased from Selleck Chemical (Boston, MA, USA) and MEK inhibitor GSK1120212 (Trametinib) was purchased from ChemieTek (Indianapolis, IN, USA).

Wei B., Michael H.T., Halsey C.H., Peer C.J., Adhikari A., Dwyer J.E., Hoover S.B., El Meskini R., Kozlov S., Weaver Ohler Z., Figg W.D., Merlino G, & Simpson R.M. (2016). Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment Cell & Melanoma Research, 29(6), 643-655.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!